Autism Drugs Pipeline Market Overview
Autism, also known as a complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication, and repetitive behaviors. Risk factors include the child’s sex, family history, fragile X syndrome, Tourette syndrome, and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.
The Autism drugs in development market research report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.
What are the key targets in the Autism pipeline products market?
The key targets in the Autism pipeline products market are 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 7, Amine Oxidase [Flavin Containing] B, Cannabinoid Receptor 1, Cannabinoid Receptor 2, D3 Dopamine Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine, and others.
Autism Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
What are the key mechanisms of action in the Autism pipeline products market?
The key mechanisms of action in the Autism pipeline products market are 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Amine Oxidase [Flavin Containing] B Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, D2 Dopamine Receptor Agonist, D3 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine Inhibitor, and others.
Autism Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
What are the key routes of administration in the Autism pipeline products market?
The key routes of administration in the Autism pipeline products market are oral, nasal, parenteral, inhalational, intramuscular, intrathecal, subcutaneous, and sublingual.
Autism Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
What are the different molecule types in the Autism pipeline products market?
The different molecule types in the Autism pipeline products market are small molecule, biologic, antibody, cell therapy, enzyme, and synthetic peptide.
Autism Pipeline Products Market Analysis by Molecule Type
To know more about molecule types, download a free report sample
Which are the major companies in the Autism pipeline products market?
Some of the major companies in the Autism pipeline products market are MD Healthcare Inc, 4D Pharma Plc, Intra-Cellular Therapies Inc, Oryzon Genomics SA, RogCon Inc, Zelira Therapeutics Ltd, AgeneBio Inc, AgoneX Biopharmaceuticals Inc, Allos Pharma Inc, and AsiaBiome.
Autism Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Scope
| Key targets | 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 7, Amine Oxidase [Flavin Containing] B, Cannabinoid Receptor 1, Cannabinoid Receptor 2, D3 Dopamine Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine, and Others |
| Key mechanism of action | 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Amine Oxidase [Flavin Containing] B Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, D2 Dopamine Receptor Agonist, D3 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine Inhibitor, and Others |
| Key routes of administration | Oral, Nasal, Parenteral, Inhalational, Intramuscular, Intrathecal, Subcutaneous, and Sublingual |
| Molecule type | Small Molecule, Biologic, Antibody, Cell Therapy, Enzyme, and Synthetic Peptide |
| Major companies | MD Healthcare Inc, 4D Pharma Plc, Intra-Cellular Therapies Inc, Oryzon Genomics SA, RogCon Inc, Zelira Therapeutics Ltd, AgeneBio Inc, AgoneX Biopharmaceuticals Inc, Allos Pharma Inc, and AsiaBiome |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Autism (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Stakeholders
Table of Contents
Tables
List of Tables
Number of Products under Development for Autism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Autism – Pipeline by 4D Pharma Plc, 2022
Autism – Pipeline by AgeneBio Inc, 2022
Autism – Pipeline by AgoneX Biopharmaceuticals Inc, 2022
Autism – Pipeline by Allos Pharma Inc, 2022
Autism – Pipeline by AsiaBiome, 2022
Autism – Pipeline by Axial Therapeutics Inc, 2022
Autism – Pipeline by Cennerv Pharma (S) Pte Ltd, 2022
Autism – Pipeline by ChunLab Inc, 2022
Autism – Pipeline by Cognosetta Inc, 2022
Autism – Pipeline by Curemark LLC, 2022
Autism – Pipeline by Enterin Inc, 2022
Autism – Pipeline by Epigen Biosciences Inc, 2022
Autism – Pipeline by EuMentis Therapeutics Inc, 2022
Autism – Pipeline by Herophilus, 2022
Autism – Pipeline by Hopstem Biotechnology LLC, 2022
Autism – Pipeline by iCELL Biotechnology Co Ltd, 2022
Autism – Pipeline by ImmunoBiome Inc, 2022
Autism – Pipeline by Immuron Ltd, 2022
Autism – Pipeline by Intra-Cellular Therapies Inc, 2022
Autism – Pipeline by Intrinsic Medicine Inc, 2022
Autism – Pipeline by Johnson & Johnson, 2022
Autism – Pipeline by Kuzani Pharmaceuticals Inc, 2022
Autism – Pipeline by MD Healthcare Inc, 2022
Autism – Pipeline by Omeros Corp, 2022
Autism – Pipeline by OptiNose Inc, 2022
Autism – Pipeline by Oryzon Genomics SA, 2022
Autism – Pipeline by Palisades Therapeutics, 2022
Autism – Pipeline by Panorama Researchama Research, 2022
Autism – Pipeline by Park Active Molecules, 2022
Autism – Pipeline by Reviva Pharmaceuticals Inc, 2022
Autism – Pipeline by Richter Gedeon Nyrt, 2022
Autism – Pipeline by RogCon Inc, 2022
Autism – Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, 2022
Autism – Pipeline by Scioto Biosciences Inc, 2022
Autism – Pipeline by SciSparc Ltd, 2022
Autism – Pipeline by Sengenics Corp Pte Ltd, 2022
Autism – Pipeline by Standigm Inc, 2022
Autism – Pipeline by Stem Cell Medicine Ltd, 2022
Autism – Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022
Autism – Pipeline by Tempero Bio, 2022
Autism – Pipeline by The Greater Cannabis Company Inc, 2022
Autism – Pipeline by Vanda Pharmaceuticals Inc, 2022
Autism – Pipeline by Yamo Pharmaceuticals LLC, 2022
Autism – Pipeline by Zelira Therapeutics Ltd, 2022
Autism – Dormant Projects, 2022
Autism – Dormant Projects, 2022 (Contd..1)
Autism – Discontinued Products, 2022
Graphs
List of Figures
Number of Products under Development for Autism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022












